The smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.
Hideki Garren, MD, PhD
Advertisement
Articles by Hideki Garren, MD, PhD
The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.
The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).
Advertisement
Latest Updated Articles
Hideki Garren, MD, PhD: The ORATORIO-HAND Trial in PPMSPublished: October 11th 2018 | Updated:
Hideki Garren, MD, PhD: Measuring MS Progression With Floodlight OpenPublished: October 18th 2018 | Updated:
Hideki Garren, MD, PhD: Past and Future Ocrelizumab AnalysesPublished: April 27th 2018 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Parkinson Agent Tavapadon Shows Continued Efficacy, Safety in Phase 3 TEMPO-4 Trial
2
Elecsys pTau181 Test Cleared, Tividenofusp Alfa PDUFA Pushed Back, Phase 4 LOTUS Study Highlights Real-World Benefit of Trofinetide
3
NeurologyLive® Friday 5 — October 17, 2025
4
Bilateral MR-Guided Focused Ultrasound Shows Benefit for Managing Parkinson Motor Complications in Phase 3 Trial
5
